Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate, comparatively to a placebo, the activity of oral AB1010,
administered at three dose levels during 4 months to patients with severe persistent
corticosteroid dependent asthma, assessed on :
- the decrease in corticosteroid therapy
- the asthma control improvement (symptomatic scores, rescue medication intake,
respiratory function)
- the pharmacokinetic profile of AB1010
- clinical and biological safety parameters